Contract Development and Manufacturing Organization (CDMO) / Pharmaceutical Services
Strategic Profile
The company is expanding its operational footprint across the United States and Europe to meet rising global demand for high-quality drug development and manufacturing solutions, while enhancing its ability to support customers throughout the entire product lifecycle. Cambrex specializes in complex small molecule development projects and active pharmaceutical ingredient (API) manufacturing.
Cyborg Score Rationale
Cambrex demonstrates strong market positioning in the CDMO sector with significant capital investments in expansion ($120M in US operations) announced in 2025. The company is executing a clear growth strategy with facility modernization across multiple geographies. However, as a private company, visibility into full financial performance and profitability metrics is limited.
Top Insights
(March 2026) Completed initial engineering studies for a new large-scale API manufacturing plant in Charles City, Iowa, representing progress toward a $120 million investment in expanding US API manufacturing capabilities.
Actively investing in upgrading US facilities to increase production capacity and improve technological capabilities, with focus on complex small molecule development and API manufacturing.
Expanding European operations through investments in key pharmaceutical hub facilities, including new production lines and expanded laboratory capabilities.
Employed 1,744 people as of February 2026.
Named Competitors
Catalent — Global CDMO providing drug development and manufacturing services
CordenPharma — Contract development and manufacturing organization
Recipharm — European CDMO and specialized pharma services provider
Theorem Clinical Research — Clinical research and manufacturing services
Recent Developments
(March 2026) Completed initial engineering studies for new large-scale API manufacturing plant in Charles City, Iowa
(March 2026) Announced significant expansion of US and European operations to meet growing demand
(October 2025) Unveiled $120 million investment to expand API manufacturing and strengthen US drug supply
Open the full interactive Cambrex Corporation report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.